Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals
Background Cystic fibrosis (CF) is a genetic condition caused by variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that primarily impacts the lungs. Treatments historically have been symptomatic to improve airway clearance and treat infection. However, CFTR modulator dr...
Main Authors: | Christopher Ward, Iram Haq, Shelina Visram, Maryam Almulhem, Nuala Harnett, Stephanie Graham |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-10-01
|
Series: | BMJ Open Respiratory Research |
Online Access: | https://bmjopenrespres.bmj.com/content/9/1/e001420.full |
Similar Items
-
Elexacaftor/Tezacaftor/Ivacaftor Accelerates Wound Repair in Cystic Fibrosis Airway Epithelium
by: Onofrio Laselva, et al.
Published: (2022-09-01) -
Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome
by: Sophia T. Pallenberg, et al.
Published: (2022-10-01) -
Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
by: Lijia Zhang, et al.
Published: (2022-12-01) -
Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
by: Linus Piehler, et al.
Published: (2023-04-01) -
The effect of elexacaftor/tezacaftor/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis
by: Sarah Allgood, et al.
Published: (2023-09-01)